Valuation : Opus Genetics, Inc.

Market Cap 389M 334M 314M 287M 537M 36.74B 538M 3.73B 1.44B 18.82B 1.46B 1.43B 59.94B P/E 2026 *
-4.74x
P/E 2027 * -6.54x
Enterprise Value 389M 334M 314M 287M 537M 36.74B 538M 3.73B 1.44B 18.82B 1.46B 1.43B 59.94B EV / Sales 2026 *
31.3x
EV / Sales 2027 * 30.2x
Free-Float
89.06%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Opus Genetics, Inc.

1 day+1.52%
1 week+29.01%
Current month+29.01%
1 month+27.60%
3 months+15.88%
6 months-4.50%
Current year+132.34%
1 week 3.86
Extreme 3.86
4.83
1 month 3.51
Extreme 3.511
4.83
Current year 1.88
Extreme 1.88
5.81
1 year 1.32
Extreme 1.32
5.81
3 years 0.65
Extreme 0.65
5.81
5 years 0.65
Extreme 0.65
6.6
10 years 0.65
Extreme 0.65
13.81
Manager TitleAgeSince
Chief Executive Officer 42 2023-10-31
Director of Finance/CFO 52 2025-09-01
President 60 2024-10-21
Director TitleAgeSince
Director/Board Member 77 2020-10-31
Chairman 56 2019-11-30
Director/Board Member 59 2020-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/23/26 Sell

Chief Financial Officer

-7,783 0.0094%
7/23/26 Sell

Chairperson

-7,429 0.0090%
7/23/26 Sell

Chief Executive Officer

-9,475 0.0115%
Change 5-day change 1-year change 3-year change Capi.($)
+1.52%+29.01%+267.72%+17.04% 389M
-0.88%-0.64%+58.05%+100.51% 1,024B
-1.15%+3.53%+54.25%+71.99% 663B
-1.44%+0.02%+20.65%+72.22% 453B
-0.95%+0.23%+28.96%+37.78% 352B
-3.18%+1.78%+20.66%+41.55% 304B
+0.30%+0.60%-0.40%+11.25% 252B
-1.55%+1.71%+54.15%+71.87% 236B
+0.02%+2.24%-14.59%-55.80% 206B
-0.15%+3.18%+31.24%+104.21% 187B
Average -0.75%+3.82%+52.07%+47.26% 367.88B
Weighted average by Cap. -1.07%+0.64%+37.23%+64.50%

Financials

2026 *2027 *
Net sales 12.41M 10.67M 10.04M 9.16M 17.14M 1.17B 17.2M 119M 46.01M 601M 46.61M 45.59M 1.91B 12.88M 11.08M 10.42M 9.51M 17.79M 1.22B 17.85M 124M 47.75M 624M 48.37M 47.32M 1.99B
Net income -91.92M -79.05M -74.35M -67.87M -127M -8.69B -127M -882M -341M -4.45B -345M -338M -14.18B -68.25M -58.69M -55.2M -50.39M -94.24M -6.45B -94.55M -655M -253M -3.31B -256M -251M -10.53B
Net Debt - -
Logo Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Employees
28
Date Price Change Volume
26-09-04 US$4.670 +1.52% 2,239,733
26-09-03 US$4.600 +3.37% 4,425,604
26-09-02 US$4.450 +16.19% 4,998,100
26-09-01 US$3.830 +5.80% 868,852
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
4.670USD
Average target price
10.71USD
Spread / Average Target
+129.25%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!